High doses of biotin in chronic progressive multiple sclerosis: A pilot study.
-
MiSsty
LATE BREAKING NEWS AT ECTRIMS 2015...AND BIOTIN
LATE BREAKING NEWS AT ECTRIMS 2015...AND BIOTIN
LATE-BREAKING NEWS AT ECTRIMS 2015: ... AND BIOTIN Biotin is part of the B complex group of vitamins and is often referred to as vitamin H (for Haar und Haut, or hair and skin), but a recent study suggested that its benefits may extend beyond the scalp. A pilot study in France administered high-dose biotin (100-300 mg/day) to 23 consecutive patients with primary- or secondary-progressive MS for up to 36 months (Sedel et al. Mult Scler Relat Disord 2015;4:159-169). Improvements were seen in visual evoked potentials in two patients, and 16 of 18 patients with spinal cord involvement were rated as improved.
The group has now reported the results of a study of high-dose biotin (MD1003) in SPMS/PPMS patients without baseline inflammatory activity (Tourbah et al. ECTRIMS 2015; abstract LB223). A total of 154 patients were randomized to MD1003 100 mg tid or placebo for one year. Overall, 13 of 103 patients in the MD1003 group (12.62% vs. 0% with placebo) met the primary endpoint of improvement from baseline in EDSS score or timed 25-foot walk at nine months and confirmed at 12 months. The mean change in EDSS score was -0.03 with MD1003 compared to +0.14 with placebo; this difference was significant. The authors noted that clinical benefits were more pronounced in SPMS patients compared to the PPMS group.
TOPICS: ECTRIMS 2015, MS
. AND BIOTIN Biotin is part of the B complex group of vitamins and is often referred to as vitamin H (for Haar und Haut, or hair and skin), but a recent study suggested that its benefits may extend beyond the scalp. A pilot study in France administered high-dose biotin (100-300 mg/day) to 23 consecutive patients with primary- or secondary-progressive MS for up to 36 months (Sedel et al. Mult Scler Relat Disord 2015;4:159-169). Improvements were seen in visual evoked potentials in two patients, and 16 of 18 patients with spinal cord involvement were rated as improved.
The group has now reported the results of a study of high-dose biotin (MD1003) in SPMS/PPMS patients without baseline inflammatory activity (Tourbah et al. ECTRIMS 2015; abstract LB223). A total of 154 patients were randomized to MD1003 100 mg tid or placebo for one year. Overall, 13 of 103 patients in the MD1003 group (12.62% vs. 0% with placebo) met the primary endpoint of improvement from baseline in EDSS score or timed 25-foot walk at nine months and confirmed at 12 months. The mean change in EDSS score was -0.03 with MD1003 compared to +0.14 with placebo; this difference was significant. The authors noted that clinical benefits were more pronounced in SPMS patients compared to the PPMS group.
TOPICS: ECTRIMS 2015, MS
LATE-BREAKING NEWS AT ECTRIMS 2015: ... AND BIOTIN Biotin is part of the B complex group of vitamins and is often referred to as vitamin H (for Haar und Haut, or hair and skin), but a recent study suggested that its benefits may extend beyond the scalp. A pilot study in France administered high-dose biotin (100-300 mg/day) to 23 consecutive patients with primary- or secondary-progressive MS for up to 36 months (Sedel et al. Mult Scler Relat Disord 2015;4:159-169). Improvements were seen in visual evoked potentials in two patients, and 16 of 18 patients with spinal cord involvement were rated as improved.
The group has now reported the results of a study of high-dose biotin (MD1003) in SPMS/PPMS patients without baseline inflammatory activity (Tourbah et al. ECTRIMS 2015; abstract LB223). A total of 154 patients were randomized to MD1003 100 mg tid or placebo for one year. Overall, 13 of 103 patients in the MD1003 group (12.62% vs. 0% with placebo) met the primary endpoint of improvement from baseline in EDSS score or timed 25-foot walk at nine months and confirmed at 12 months. The mean change in EDSS score was -0.03 with MD1003 compared to +0.14 with placebo; this difference was significant. The authors noted that clinical benefits were more pronounced in SPMS patients compared to the PPMS group.
TOPICS: ECTRIMS 2015, MS
. AND BIOTIN Biotin is part of the B complex group of vitamins and is often referred to as vitamin H (for Haar und Haut, or hair and skin), but a recent study suggested that its benefits may extend beyond the scalp. A pilot study in France administered high-dose biotin (100-300 mg/day) to 23 consecutive patients with primary- or secondary-progressive MS for up to 36 months (Sedel et al. Mult Scler Relat Disord 2015;4:159-169). Improvements were seen in visual evoked potentials in two patients, and 16 of 18 patients with spinal cord involvement were rated as improved.
The group has now reported the results of a study of high-dose biotin (MD1003) in SPMS/PPMS patients without baseline inflammatory activity (Tourbah et al. ECTRIMS 2015; abstract LB223). A total of 154 patients were randomized to MD1003 100 mg tid or placebo for one year. Overall, 13 of 103 patients in the MD1003 group (12.62% vs. 0% with placebo) met the primary endpoint of improvement from baseline in EDSS score or timed 25-foot walk at nine months and confirmed at 12 months. The mean change in EDSS score was -0.03 with MD1003 compared to +0.14 with placebo; this difference was significant. The authors noted that clinical benefits were more pronounced in SPMS patients compared to the PPMS group.
TOPICS: ECTRIMS 2015, MS
-
Corinne
-
MiSsty
-
isabella
ik ben sinds juni 2015 aan de biotine. Maar een aantal keer gestopt en weer begonnen omdat de spierstijfheid zo extreem werd.
Pijnlijk en ook moeilijkheden met transfers, slapen, van alles geprobeerd om de spierstijfheid te verminderen maar niets hielp.
Nu heb ik de afgelopen twee weken stukken minder last van spierstijfheid, strek- en buigspasme. Transfers gaan goed, ik voel me goed en ik slaap weer goed.
Wilde dit slecht even delen, want ik hoor dat meer mensen deze bijwerking (spierstijfheid) hebben. Bij mij is het dus overgegaan.
Wat ik het grootste voordeel ervaar van de biotine is dat ik weer normaal kan plassen: geen urgentie en de frequentie is stukken minder. Nu zit er gemiddeld 4 uur tussen. Dit vind ik een zeer grote winst.
Pijnlijk en ook moeilijkheden met transfers, slapen, van alles geprobeerd om de spierstijfheid te verminderen maar niets hielp.
Nu heb ik de afgelopen twee weken stukken minder last van spierstijfheid, strek- en buigspasme. Transfers gaan goed, ik voel me goed en ik slaap weer goed.
Wilde dit slecht even delen, want ik hoor dat meer mensen deze bijwerking (spierstijfheid) hebben. Bij mij is het dus overgegaan.
Wat ik het grootste voordeel ervaar van de biotine is dat ik weer normaal kan plassen: geen urgentie en de frequentie is stukken minder. Nu zit er gemiddeld 4 uur tussen. Dit vind ik een zeer grote winst.
-
Christian
-
pokey
vraagje betreffende spierstijfheid
vraagje betreffende spierstijfheid
ik slik sinds een paar weken biotin, maar nog lang niet de hoge dosis uit de onderzoeken
ik slik 2 pillen van 10.000 mcg (ipv 10 tot 30 dus :) ) maar heb ook het idee dat mijn slechtere linkerbeen stijver wordt.
verder geen gekke dingen die om MS achteruitgang lijken, alleen dat gekke been. daarom ben ik benieuwd of spierstijfheid (geen spasme alleen meer spanning) met zulke lage dosis ook al een bijwerking zou kunnen zijn?
ik reageer vaak wel vlot/extreem op medicatie
ik slik sinds een paar weken biotin, maar nog lang niet de hoge dosis uit de onderzoeken
ik slik 2 pillen van 10.000 mcg (ipv 10 tot 30 dus :) ) maar heb ook het idee dat mijn slechtere linkerbeen stijver wordt.
verder geen gekke dingen die om MS achteruitgang lijken, alleen dat gekke been. daarom ben ik benieuwd of spierstijfheid (geen spasme alleen meer spanning) met zulke lage dosis ook al een bijwerking zou kunnen zijn?
ik reageer vaak wel vlot/extreem op medicatie
-
isabella
[url]http://multiplesclerosisnewstoday.com/2 ... essive-ms/[/url]
Alle patienten Uit de studie die MD 1003 slikten, Bleken na twee jaar stabiel. Dus 100% van de patiënten groep geen progressie.
Lees ik dit juist?
Alle patienten Uit de studie die MD 1003 slikten, Bleken na twee jaar stabiel. Dus 100% van de patiënten groep geen progressie.
Lees ik dit juist?
-
Klick
[QUOTE=isabella;1044259][url]http://multiplesclerosisnewstoday.com/2 ... essive-ms/[/url]
Alle patienten Uit de studie die MD 1003 slikten, Bleken na twee jaar stabiel. Dus 100% van de patiënten groep geen progressie.
Lees ik dit juist?[/QUOTE]
Beetle knippen en plakken voor Ik het zelf Kon volgen.. Zie hier het resultaat
The MS-SPI trial, focusing on [B]not-active progressive[/B] MS, a difficult-to-treat form of ms
the proportion of patients who improved 12.6 percent of patients after nine months, confirmed at 12 months, and equivalent to a reversed progression. During the same period, none of the placebo-treated patients improved.
and 15.4 percent at 24 months
(dus 15.4% van [B]progressieve[/B] patienten had herstel van klachten):
Alle patienten Uit de studie die MD 1003 slikten, Bleken na twee jaar stabiel. Dus 100% van de patiënten groep geen progressie.
Lees ik dit juist?[/QUOTE]
Beetle knippen en plakken voor Ik het zelf Kon volgen.. Zie hier het resultaat
The MS-SPI trial, focusing on [B]not-active progressive[/B] MS, a difficult-to-treat form of ms
the proportion of patients who improved 12.6 percent of patients after nine months, confirmed at 12 months, and equivalent to a reversed progression. During the same period, none of the placebo-treated patients improved.
and 15.4 percent at 24 months
(dus 15.4% van [B]progressieve[/B] patienten had herstel van klachten):